FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a report issued on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on FGEN. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of FibroGen in a report on Tuesday. William Blair reiterated a “market perform” rating on shares of FibroGen in a report on Tuesday, April 1st.

FibroGen Trading Up 1.3%

NASDAQ:FGEN opened at $0.31 on Friday. FibroGen has a 1-year low of $0.18 and a 1-year high of $1.53. The firm has a market capitalization of $30.92 million, a price-to-earnings ratio of -0.25 and a beta of 0.86. The business’s fifty day moving average price is $0.32 and its 200 day moving average price is $0.41.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.19). The firm had revenue of $2.70 million during the quarter, compared to the consensus estimate of $2.00 million. Equities analysts forecast that FibroGen will post -0.8 earnings per share for the current year.

Insider Activity

In other news, Director James A. Schoeneck purchased 250,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was acquired at an average price of $0.35 per share, with a total value of $87,500.00. Following the purchase, the director now owns 323,722 shares in the company, valued at $113,302.70. This represents a 339.11% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thane Wettig purchased 145,000 shares of the stock in a transaction that occurred on Monday, March 24th. The stock was purchased at an average cost of $0.35 per share, with a total value of $50,750.00. Following the purchase, the chief executive officer now owns 543,329 shares in the company, valued at $190,165.15. This represents a 36.40% increase in their position. The disclosure for this purchase can be found here. 3.07% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On FibroGen

A number of large investors have recently added to or reduced their stakes in FGEN. Armistice Capital LLC boosted its position in FibroGen by 25.0% during the first quarter. Armistice Capital LLC now owns 8,500,000 shares of the biopharmaceutical company’s stock worth $2,634,000 after purchasing an additional 1,700,000 shares during the period. JPMorgan Chase & Co. boosted its position in FibroGen by 430.7% during the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after purchasing an additional 1,358,194 shares during the period. Renaissance Technologies LLC boosted its position in FibroGen by 80.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after purchasing an additional 605,572 shares during the period. Mackenzie Financial Corp boosted its position in FibroGen by 416.6% during the fourth quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 441,083 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in FibroGen during the fourth quarter worth approximately $205,000. Institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.